Financial Consulate’s Capricor Therapeutics CAPR Stock Holding History

Financial Consulate’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.08K	Buy	+220	New	+$2.44K	﹤0.01%	1107

Other funds holding CAPR

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Wolff Wiese Magana Carslbad, California $218M AUM 37.48% 1-Year Est. Return

Financial Consulate's CAPR Position: Q3 2026 in Review

Financial Consulate opened a new position in Capricor Therapeutics (CAPR) in Q3 2026: 220 shares worth $2.08K. The stake represents ﹤0.01% of the portfolio and ranks #1107 among its holdings.

12 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

Financial Consulate held 220 shares of Capricor Therapeutics worth $2.08K as of Q3 2026.
Capricor Therapeutics was a new Financial Consulate position in Q3 2026.
Capricor Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1107 holding.
12 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.